What is Janux Therapeutics's preferred stock?

Janux Therapeutics (JANX) reported preferred stock of $0 in Q1 2026.

What does preferred stock mean?

Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.

Janux Therapeutics JANX Preferred Stock

Preferred Stock at other companies

Cullinan Therapeutics, Inc.CGEM

$0—

Nektar TherapeuticsNKTR

$0—

Inhibrx Biosciences, Inc.INBX

$0—

Summit TherapeuticsSMMT

$0—

Vir Biotechnology, Inc.VIR

$0—

Bicara TherapeuticsBCAX

$0—

Other financials

Income statement

See full

Revenue$3.7M—

Operating income-$34.2M+2.0%

Net income-$24.4M-3.6%

EPS (diluted)-$0.39-2.6%

Balance sheet

See full

Cash & equivalents$51.8M-29.7%

Total debt$21.6M-4.6%

Total equity$941.5M-7.0%

Total assets$1.0B-2.1%

Cash flow

See full

Operating cash flow-$12.3M+27.5%

CapEx$273.0K-26.4%

Free cash flow-$12.6M+27.5%

Valuation

See full

Market cap$892.81M-36.1%

Enterprise value$862.55M-35.9%

P/S65×-84.6×

Profitability

See full

Operating margin-1,143.1%-65.1pp

Net margin-833.6%+0.9pp

FCF margin-571.6%+98.3pp

Returns & leverage

See full

Return on equity-11.7%+4.1pp

Debt / equity0×0.0×

Current ratio17×-41.5×

Where this comes from

Reported directly by Janux Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Janux Therapeutics's preferred stock?: Janux Therapeutics (JANX) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?: Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.